The objective of this study is to collect and assess the information about long-term safety and effectiveness of Benlysta for intravenous injection and Benlysta for subcutaneous injection (hereinafter referred to as "Benlysta") in daily clinical practice. The aim of conducting this drug use investigation (DUI) in all subjects until data are accumulated from a certain number of subjects after Benlysta being marketed, data will be collected on safety and effectiveness of Benlysta in an early stage and thereby to take the necessary measures for proper use of Benlysta. Approximately 600 subjects will be enrolled in to this study. The observation period per subject will be 52 weeks from the start of Benlysta administration. BENLYSTA is the registered trademark of GlaxoSmithKline (GSK) group of companies.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change from Baseline in Safety of Estrogens in Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA SLEDAI)
Timeframe: Baseline and up to 52 weeks
Change from Baseline in Physician's Global Assessment (PGA) score
Timeframe: Baseline and up to 52 weeks
Change from Baseline in Lupus Impact Tracker score
Timeframe: Baseline and up to 52 weeks
Number of subjects with abnormal change in laboratory parameters
Timeframe: Baseline and up to 52 weeks
Number of subjects with adverse events (AE) and serious adverse events (SAE)
Timeframe: Up to 52 weeks
Number of subjects with adverse drug reactions (ADR) of events defined as a priority study matter
Timeframe: Up to 52 weeks